BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Candeias EM, Sebastião IC, Cardoso SM, Correia SC, Carvalho CI, Plácido AI, Santos MS, Oliveira CR, Moreira PI, Duarte AI. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World J Diabetes 2015; 6(6): 807-827 [PMID: 26131323 DOI: 10.4239/wjd.v6.i6.807]
URL: https://www.wjgnet.com/1948-9358/full/v6/i6/807.htm
Number Citing Articles
1
Joana M. Gaspar, Filipa I. Baptista, M. Paula Macedo, António F. Ambrósio. Inside the Diabetic Brain: Role of Different Players Involved in Cognitive DeclineACS Chemical Neuroscience 2016; 7(2): 131 doi: 10.1021/acschemneuro.5b00240
2
Ngom Issa Isaac, Decloquement Philippe, Armstrong Nicholas, Didier Raoult, Chabrière Eric. Metaproteomics of the human gut microbiota: Challenges and contributions to other OMICSClinical Mass Spectrometry 2019; 14: 18 doi: 10.1016/j.clinms.2019.06.001
3
R. U. Ostrovskaya, T. A. Antipova, S. V. Nikolaev, S. V. Kruglov, I. V. Ozerova, T. A. Gudasheva, S. B. Seredenin. Deficit of Neurotrophins in Experimental Diabetes – Correction with a Proline-Containing DipeptideNeuroscience and Behavioral Physiology 2019; 49(7): 809 doi: 10.1007/s11055-019-00806-z
4
Yingna Mei, Yubing Li, Yanxiang Cheng, Ling Gao. The effect of gastric bypass surgery on cognitive function of Alzheimer's disease and the role of GLP1-SGLT1 pathwayExperimental Neurology 2023; 363: 114377 doi: 10.1016/j.expneurol.2023.114377
5
Brian DellaValle, Gitte S. Brix, Birgitte Brock, Michael Gejl, Anne M. Landau, Arne Møller, Jørgen Rungby, Agnete Larsen. Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis RatsFrontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00433
6
Y. H. Lee-Barkey, B. Stratmann, D. Tschöpe. Inkretinbasierte DiabetesmedikamenteDer Diabetologe 2017; 13(7): 498 doi: 10.1007/s11428-017-0269-8
7
Lei Meng, Zhe Wang, Hong-Fang Ji, Liang Shen. Causal association evaluation of diabetes with Alzheimer's disease and genetic analysis of antidiabetic drugs against Alzheimer's diseaseCell & Bioscience 2022; 12(1) doi: 10.1186/s13578-022-00768-9
8
Alireza Mohammad Karim. Principles and Biomedical Applications of Self-Assembled Peptides: Potential Treatment of Type 2 Diabetes MellitusPharmaceutics 2024; 16(11): 1442 doi: 10.3390/pharmaceutics16111442
9
Qian Shi, Shuqian Liu, Vivian A Fonseca, Tina K Thethi, Lizheng Shi. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitusBMJ Open 2019; 9(7): e024954 doi: 10.1136/bmjopen-2018-024954
10
Grazyna Lietzau, Thomas Nyström, Claes-Göran Östenson, Vladimer Darsalia, Cesare Patrone. Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4Oncotarget 2016; 7(5): 5865 doi: 10.18632/oncotarget.6823
11
A Young Sim, Sumit Barua, Jong Youl Kim, Yong-ho Lee, Jong Eun Lee. Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes MellitusFrontiers in Neuroscience 2021; 15 doi: 10.3389/fnins.2021.708547
12
Yan Zhang, Yang Liu, V. Wee Yong, Mengzhou Xue. Omarigliptin inhibits brain cell ferroptosis after intracerebral hemorrhageScientific Reports 2023; 13(1) doi: 10.1038/s41598-023-41635-y
13
WenXing Fan, Zhang Liang, Hua Xiao, QiuPing Yang. Therapeutic efficacy of liraglutide on diabetic nephropathy mice by inhibiting inflammatory factorsEuropean Journal of Inflammation 2018; 16 doi: 10.1177/2058739218819283
14
Yunfang Su, Ningning Liu, Zijuan Zhang, Hao Li, Jinlian Ma, Ye Yuan, Ming Shi, Jihong Liu, Zhenrong Zhao, Zhenqiang Zhang, Christian Holscher. Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse modelsEuropean Journal of Pharmacology 2022; 926: 175029 doi: 10.1016/j.ejphar.2022.175029
15
Yang Gou, Michael W. Schwartz. How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?Journal of Clinical Investigation 2023; 133(19) doi: 10.1172/JCI174597
16
Ahmed M. Kabel, Mohamed S. Omar, A. Alhadhrami, Salman S. Alharthi, Majed M. Alrobaian. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1Physiology & Behavior 2018; 188: 108 doi: 10.1016/j.physbeh.2018.01.028
17
Rita Citraro, Michelangelo Iannone, Antonio Leo, Carmen De Caro, Valentina Nesci, Martina Tallarico, Karim Abdalla, Ernesto Palma, Franco Arturi, Giovambattista De Sarro, Andrew Constanti, Emilio Russo. Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesisBrain Research Bulletin 2019; 153: 133 doi: 10.1016/j.brainresbull.2019.08.001
18
Young-Kook Kim, Oh Yoen Kim, Juhyun Song. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic FunctionFrontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.01270
19
Qiu-Ju Wang, Yi-Zhe Cui, Xiu-Ying Zhang, Jing Su. Effect of early weaning on the expression of excitatory amino acid transporter 1 in the jejunum and ileum of pigletsMolecular Medicine Reports 2017; 16(5): 6518 doi: 10.3892/mmr.2017.7421
20
Christian Hölscher. Brain insulin resistance: role in neurodegenerative disease and potential for targetingExpert Opinion on Investigational Drugs 2020; 29(4): 333 doi: 10.1080/13543784.2020.1738383
21
Hava AÇAR KAYA, Mehmet Aydın AKALAN, İsmail TÜRKMENOĞLU. Effect of Glukagon-Like Peptide-1 Analog Liraglutide On Neural Tube Development In Chick Embryo ModelKocatepe Veterinary Journal 2022;  doi: 10.30607/kvj.1103958
22
J. A. Hutchinson, S. Burholt, I. W. Hamley. Peptide hormones and lipopeptides: from self‐assembly to therapeutic applicationsJournal of Peptide Science 2017; 23(2): 82 doi: 10.1002/psc.2954
23
R. Loera‐Valencia, A. Cedazo‐Minguez, P.A. Kenigsberg, G. Page, A.I. Duarte, P. Giusti, M. Zusso, P. Robert, G. B. Frisoni, Annamaria Cattaneo, M. Zille, J. Boltze, N. Cartier, L. Buee, G. Johansson, B. Winblad. Current and emerging avenues for Alzheimer's disease drug targetsJournal of Internal Medicine 2019; 286(4): 398 doi: 10.1111/joim.12959
24
Morgana Prá, Gabriela Kozuchovski Ferreira, Aline Haas de Mello, Rosiane de Bona Schraiber, Larissa Colonetti Cardoso, Luana da Rosa Souza, Naiana da Rosa, Jucélia Jeremias Fortunato, Gislaine Tezza Rezin. Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult ratsBiochemistry and Cell Biology 2016; 94(5): 451 doi: 10.1139/bcb-2016-0016
25
Brian DellaValle, Gitte S. Brix, Birgitte Brock, Michael Gejl, Jørgen Rungby, Agnete Larsen. Oral Administration of Sitagliptin Activates CREB and Is Neuroprotective in Murine Model of Brain TraumaFrontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00450
26
Cosmin Sonea, Anca-Liliana Opris, Manuel F. Casanova, Ioan Opris, Marian Vladimir Constantinescu. The Physics of the Mind and Brain DisordersSpringer Series in Cognitive and Neural Systems 2017; 11: 469 doi: 10.1007/978-3-319-29674-6_21
27
Vladimer Darsalia, Thomas Klein, Thomas Nyström, Cesare Patrone. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potentialNeuropharmacology 2018; 136: 280 doi: 10.1016/j.neuropharm.2017.08.022
28
Marcio C. Mancini, Maria Edna de Melo. The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mgDiabetology & Metabolic Syndrome 2017; 9(1) doi: 10.1186/s13098-017-0242-0
29
Ivan N. Tyurenkov, Denis V. Kurkin, Dmitry A. Bakulin, Elena V. Volotova, Evgeny I. Morkovin, Mikhail A. Chafeev, Ruben N. Karapetian. Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00543
30
Andrei C. Sposito, Otávio Berwanger, Luiz Sérgio F. de Carvalho, José Francisco Kerr Saraiva. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome dataCardiovascular Diabetology 2018; 17(1) doi: 10.1186/s12933-018-0800-2
31
Violeta Arsenescu. Neuro-Immuno-Gastroenterology2016; : 157 doi: 10.1007/978-3-319-28609-9_8
32
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, Nigel H. Greig. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatmentPharmacological Research 2022; 186: 106550 doi: 10.1016/j.phrs.2022.106550
33
Shuyi Chen, Jie Sun, Gang Zhao, Ai Guo, Yanlin Chen, Rongxia Fu, Yanqiu Deng. Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic MiceNeurochemical Research 2017; 42(8): 2326 doi: 10.1007/s11064-017-2250-8
34
Justin Wan, Caesar Ferrari, Micheal Tadros. GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease TreatmentGastroenterology Insights 2024; 15(1): 191 doi: 10.3390/gastroent15010014
35
Ivan N. Tyurenkov, Alexander A. Ozerov, Denis V. Kurkin, Ekaterina O. Logvinova, Dmitry A. Bakulin, Elena V. Volotova, Dmitry D. Borodin. Structure and biological activity of endogenous and synthetic agonists of GPR119Russian Chemical Reviews 2018; 87(2): 151 doi: 10.1070/RCR4737
36
Hicham Benabdelkamel, Rajaa Sebaa, Reem H. AlMalki, Afshan Masood, Assim A. Alfadda, Anas M. Abdel Rahman. Untargeted metabolomics reveals the impact of Liraglutide treatment on metabolome profiling and metabolic pathways in type-2 diabetes mellitusSaudi Pharmaceutical Journal 2024; 32(11): 102172 doi: 10.1016/j.jsps.2024.102172
37
Laura Caberlotto, T.-Phuong Nguyen, Mario Lauria, Corrado Priami, Roberto Rimondini, Silvia Maioli, Angel Cedazo-Minguez, Giulia Sita, Fabiana Morroni, Mauro Corsi, Lucia Carboni. Cross-disease analysis of Alzheimer’s disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseasesScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-39828-5
38
Wenhui Yan, Miao Pang, Ye Yu, Xilan Gou, Peiru Si, Alina Zhawatibai, Yutong Zhang, Meng Zhang, Tingli Guo, Xinyao Yi, Lina Chen. The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosisLife Sciences 2019; 231: 116566 doi: 10.1016/j.lfs.2019.116566
39
Gang Zhang, Samuel Kim, Xiaohuan Gu, Shan Ping Yu, Ling Wei. DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic EffectsNeuroscience Bulletin 2020; 36(4): 407 doi: 10.1007/s12264-019-00446-w
40
Yvette Ruska, Anett Szilvásy-Szabó, Dóra Kővári, Andrea Kádár, Lilla Mácsai, Richárd Sinkó, Erik Hrabovszky, Balázs Gereben, Csaba Fekete. Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in miceBrain Structure and Function 2022; 227(1): 77 doi: 10.1007/s00429-021-02380-y
41
Miaad Bader, Yazhou Li, David Tweedie, Nathan A. Shlobin, Adi Bernstein, Vardit Rubovitch, Luis B. Tovar-y-Romo, Richard D. DiMarchi, Barry J. Hoffer, Nigel H. Greig, Chaim G. Pick. Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain InjuryFrontiers in Cell and Developmental Biology 2020; 7 doi: 10.3389/fcell.2019.00356
42
Mengjun Zhang, Yubin Wu, Ruonan Gao, Xinwei Chen, Ruiyu Chen, Zhou Chen. Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer's disease by suppressing NLRP2 activation in astrocytesMolecular and Cellular Endocrinology 2022; 542: 111529 doi: 10.1016/j.mce.2021.111529
43
Srikanth Jitte, Saritha Keluth, Priya Bisht, Pranay Wal, Sanjiv Singh, Krishna Murti, Nitesh Kumar. Obesity and Depression: Common Link and Possible TargetsCNS & Neurological Disorders - Drug Targets 2024; 23(12): 1425 doi: 10.2174/0118715273291985240430074053
44
Emanuel Candeias, Inês Sebastião, Susana Cardoso, Cristina Carvalho, Maria Sancha Santos, Catarina Resende Oliveira, Paula I. Moreira, Ana I. Duarte. Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic RatsMolecular Neurobiology 2017;  doi: 10.1007/s12035-017-0622-3
45
Jujun Xue, Cuiqing Wang, Chengli Pan, Haining Xing, Lijuan Xu, Xi Chen, Xuping Wang, Na Wang. Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCIExperimental and Therapeutic Medicine 2019;  doi: 10.3892/etm.2019.8339
46
Smita Jain, Ritu Singh, Sarvesh Paliwal, Swapnil Sharma. Targeting Neuroinflammation as Disease Modifying Approach to Alzheimer’s Disease: Potential and ChallengesMini-Reviews in Medicinal Chemistry 2023; 23(22): 2097 doi: 10.2174/1389557523666230511122435
47
Shuyi Chen, Mei Zhou, Jie Sun, Ai Guo, Roger Lakmal Fernando, Yanlin Chen, Peng Peng, Gang Zhao, Yanqiu Deng. DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signalingNeuropharmacology 2019; 157: 107668 doi: 10.1016/j.neuropharm.2019.107668
48
Jelena Osmanović Barilar, Ana Babić Perhoč, Ana Knezović, Jan Homolak, Davor Virag, Melita Šalković-Petrišić. The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s DiseaseBiomedicines 2023; 11(4): 1025 doi: 10.3390/biomedicines11041025
49
Ana Knezovic, Jelena Osmanovic Barilar, Ana Babic, Robert Bagaric, Vladimir Farkas, Peter Riederer, Melita Salkovic-Petrisic. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s diseaseNeuropharmacology 2018; 135: 48 doi: 10.1016/j.neuropharm.2018.02.027
50
Christian Hölscher. Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disordersBritish Journal of Pharmacology 2022; 179(4): 695 doi: 10.1111/bph.15508
51
Mohammad Amin Manavi. Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbiditiesNeuropeptides 2022; 94: 102250 doi: 10.1016/j.npep.2022.102250
52
In-Kyung Jeong. Extrapancreatic Effect of Glucagon like Peptide-1The Korean Journal of Medicine 2015; 89(4): 404 doi: 10.3904/kjm.2015.89.4.404
53
Ya-Kun Li, Dong-Xia Ma, Zhi-Min Wang, Xiao-Fan Hu, Shang-Lin Li, Hong-Zhe Tian, Meng-Jun Wang, Yan-Wen Shu, Jun Yang. The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosisPharmacological Research 2018; 131: 102 doi: 10.1016/j.phrs.2018.03.004
54
Shiliang Ji, Xingxing Zhao, Ruifang Zhu, Yongchao Dong, Lifeng Huang, Taiquan Zhang. Metformin and the risk of dementia based on an analysis of 396,332 participantsTherapeutic Advances in Chronic Disease 2022; 13 doi: 10.1177/20406223221109454
55
Brhane Teklebrhan Assefa, Gebrehiwot Gebremedhin Tafere, Dawit Zewdu Wondafrash, Meles Tekie Gidey. The Bewildering Effect of AMPK Activators in Alzheimer’s Disease: Review of the Current EvidenceBioMed Research International 2020; 2020: 1 doi: 10.1155/2020/9895121
56
Syed Obaidur Rahman, Madhu Kaundal, Mohd Salman, Apeksha Shrivastava, Suhel Parvez, Bibhu Prasad Panda, Mymoona Akhter, Mohd Akhtar, Abul Kalam Najmi. Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's diseaseEuropean Journal of Pharmacology 2020; 889: 173522 doi: 10.1016/j.ejphar.2020.173522
57
Noor Z. Al Dahhan, Elizabeth Cox, Brian J. Nieman, Donald J. Mabbott. Cross-translational models of late-onset cognitive sequelae and their treatment in pediatric brain tumor survivorsNeuron 2022; 110(14): 2215 doi: 10.1016/j.neuron.2022.04.009
58
Alla A. Boshchenko, Leonid N. Maslov, Alexander V. Mukhomedzyanov, Olga A. Zhuravleva, Alisa S. Slidnevskaya, Natalia V. Naryzhnaya, Arina S. Zinovieva, Philipp A. Ilinykh. Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor AgonistsInternational Journal of Molecular Sciences 2024; 25(9): 4900 doi: 10.3390/ijms25094900
59
Christian Hölscher. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseasesInternational Review of Neurobiology 2020; 155: 65 doi: 10.1016/bs.irn.2020.01.007